Barclays’s Zosano Pharma Corporation ZSAN Stock Holding History

Barclays’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,286	Closed	-$34K	–	5514
2022 Q1	$34K	Sell	4,286 -4,285	-50%	-$47.2K	﹤0.01%	4270
2021 Q4	$141K	Hold	8,571	–	–	﹤0.01%	3657
2021 Q3	$216K	Buy	8,571 +2,857	+50%	+$74.1K	﹤0.01%	3588
2021 Q2	$190K	Buy	5,714 +1,433	+33%	+$46.2K	﹤0.01%	3576
2021 Q1	$186K	Buy	+4,281	New	+$179K	﹤0.01%	3736
2019 Q3	–	Sell	-3	Closed	–	–	7319
2019 Q2	$0	Buy	+3	New	+$355	﹤0.01%	7445
2019 Q1	–	Sell	-43	Closed	-$3K	–	7465
2018 Q4	$3K	Sell	43 -681	-94%	-$86.2K	﹤0.01%	6658
2018 Q3	$104K	Sell	724 -819	-53%	-$120K	﹤0.01%	5514
2018 Q2	$220K	Buy	1,543 +1,377	+830%	+$207K	﹤0.01%	4637
2018 Q1	$29K	Buy	+166	New	+$55.5K	﹤0.01%	6274
2016 Q2	–	Sell	-1	Closed	-$1K	–	6744
2016 Q1	$1K	Buy	+1	New	+$1.65K	﹤0.01%	6041

Other funds holding ZSAN

CDIA

Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Barclays's ZSAN Position: Q2 2022 in Review

Barclays sold out of Zosano Pharma Corporation (ZSAN) in Q2 2022, closing a stake of 4,286 shares — an estimated $34K sold.

Barclays first reported a position in ZSAN in Q1 2016 and held it in 11 quarters. The position peaked at $220K in Q2 2018. 3 funds tracked by Wall St. Rank hold ZSAN as of Q2 2022.

Barclays reported no remaining Zosano Pharma Corporation position as of Q2 2022 after selling out during the quarter.
Barclays sold 4,286 Zosano Pharma Corporation shares in Q2 2022, an estimated $34K.
Barclays first reported a position in Zosano Pharma Corporation in Q1 2016 and held it in 11 quarters.
Barclays's Zosano Pharma Corporation position peaked at $220K in Q2 2018.
3 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.